SOTIO and Cytune Pharma, members of the PPF Group, have commenced the first dosing of cancer patients with SO-C101, a superagonist fusion protein of interleukin IL-15, it was reported on Friday.
The phase I/Ib study is to assess the safety and preliminary efficacy of the product in patients with selected advanced/metastatic solid tumours.
The first patient was treated with the product at the Institute Gustave Roussy (France). The SC103 clinical trial will also enrol patients in the Vall d'Hebron cancer centre (Spain) and, subject to receiving all the necessary approvals, at the Yale Cancer Center in New Haven, Connecticut and MD Anderson Cancer Centre in Houston, Texas.
Cytune Pharma is responsible for the clinical development of SO-C101, SOTIO is sponsor of the SC103 clinical trial.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval